Dosage Exploration of Levodopa in Combined Entacapone Therapy for Parkinson's Disease
Objective To investigate the dose of levodopa in the clinical treatment of Parkinson's disease(PD)com-bined with entacapone.Methods 68 PD patients treated in Guiyang Second People's Hospital from January 2021 to January 2023 were conveniently selected as the study objects and were divided into observation group and control group according to the dose of levodopa during treatment,with 34 cases in each group.Observation group was treated with entacapone combined with levodopa(250 mg/time),control group was treated with entacapone combined with le-vodopa(350 mg/time).The clinical efficacy,unified Parkinson's Disease Rating Scale score,inflammatory response index,oxidative stress index and adverse reaction were compared between the two groups.Results The clinical effi-cacy of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).After treatment,the unified Parkinson's disease rating scale scores of both groups were decreased,and the observation group was lower than the control group,the differences were statistically significant(all P<0.05).After treatment,the inflammatory response indexes of both groups were decreased,and the observation group was lower than the control group,the difference was statistically significant(all P<0.05).There was no significant difference in the in-cidence of adverse reactions between the two groups after treatment(P>0.05).Conclusion The clinical effect of small-dose levodopa combined with entacapone in the treatment of PD is remarkable,which can effectively improve the symptoms of PD and improve the patients'ability of daily life,improve the index of inflammatory response and oxida-tive stress,and will not increase the adverse reactions.
NETL
NSTL
万方数据
维普
